BioArctic's Fourth BrainTransporter Deal Signals Growing Platform Value -- Market Talk

Dow Jones

06/22

0756 GMT - BioArctic's fourth collaboration for its BrainTransporter technology further demonstrates the platform's long-term value beyond the Leqembi drug it helped develop for Alzheimer's disease, RBC Capital Markets analyst Natalia Webster writes. The new agreement with Eli Lilly is for the use of BrainTransporter with an undisclosed Lilly drug candidate for neurodegeneration. "The continued cadence of deal-making validates the attractiveness of the platform and management's prior commentary around good opportunities for new strategic partnerships." BioArctic will receive $30 million upfront, and will be eligible to receive additional milestone payments of up to $770 million, as well as tiered mid-single-digit royalties on future global product sales. RBC rates BioArctic at outperform with a 280 Swedish kronor price target on the stock. Shares rise 4.2% to 312 kronor. (dominic.chopping@wsj.com)

(END) Dow Jones Newswires

June 22, 2026 03:56 ET (07:56 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.

應版權方要求，你需要登入查看該內容

登入 / 註冊

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2645404262"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2645404262\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2645404262?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-22 15:56","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2645404262","market":"sg","top_or_hot":-1,"title":"BioArctic's Fourth BrainTransporter Deal Signals Growing Platform Value -- Market Talk","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     0756 GMT - BioArctic's fourth collaboration for its BrainTransporter technology further demonstrates the platform's long-term value beyond the Leqembi drug it helped develop for Alzheimer's disease, RBC Capital Markets analyst Natalia Webster writes. The new agreement with Eli Lilly is for the use of BrainTransporter with an undisclosed Lilly drug candidate for neurodegeneration. \"The continued cadence of deal-making validates the attractiveness of the platform and management's prior commentary around good opportunities for new strategic partnerships.\" BioArctic will receive $30 million upfront, and will be eligible to receive additional milestone payments of up to $770 million, as well as tiered mid-single-digit royalties on future global product sales. RBC rates BioArctic at outperform with a 280 Swedish kronor price target on the stock. Shares rise 4.2% to 312 kronor. (dominic.chopping@wsj.com) \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  June 22, 2026 03:56 ET (07:56 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BioArctic's Fourth BrainTransporter Deal Signals Growing Platform Value -- Market Talk</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBioArctic's Fourth BrainTransporter Deal Signals Growing Platform Value -- Market Talk\n</h2>\n<h4 class=\"meta\">\n<div class=\"head\" \">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time smaller\">2026-06-22 15:56</p>\n</div>\n</div>\n</h4>\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     0756 GMT - BioArctic's fourth collaboration for its BrainTransporter technology further demonstrates the platform's long-term value beyond the Leqembi drug it helped develop for Alzheimer's disease, RBC Capital Markets analyst Natalia Webster writes. The new agreement with Eli Lilly is for the use of BrainTransporter with an undisclosed Lilly drug candidate for neurodegeneration. \"The continued cadence of deal-making validates the attractiveness of the platform and management's prior commentary around good opportunities for new strategic partnerships.\" BioArctic will receive $30 million upfront, and will be eligible to receive additional milestone payments of up to $770 million, as well as tiered mid-single-digit royalties on future global product sales. RBC rates BioArctic at outperform with a 280 Swedish kronor price target on the stock. Shares rise 4.2% to 312 kronor. (dominic.chopping@wsj.com) \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  June 22, 2026 03:56 ET (07:56 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BRCTF","symbol_name":"BIOARCTIC AB","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2645404262","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2645404262","pubTimestamp":1782114960,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"0756 GMT - BioArctic's fourth collaboration for its BrainTransporter technology further demonstrates the platform's long-term value beyond the Leqembi drug it helped develop for Alzheimer's disease, RBC Capital Markets analyst Natalia Webster writes. The new agreement with Eli Lilly is for the use of BrainTransporter with an undisclosed Lilly drug candidate for neurodegeneration. \"The continued cadence of deal-making validates the attractiveness of the platform and management's prior commentary around good opportunities for new strategic partnerships.\" BioArctic will receive $30 million upfront, and will be eligible to receive additional milestone payments of up to $770 million, as well as tiered mid-single-digit royalties on future global product sales. RBC rates BioArctic at outperform with a 280 Swedish kronor price target on the stock. Shares rise 4.2% to 312 kronor. ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BRCTF":"BIOARCTIC AB","BK4139":"生物科技"},"translate_title":"BioArctic的第四笔BrainTransporter交易标志着平台价值不断增长——市场讨论","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BRCTF":1.91},"content_text":"0756 GMT - BioArctic's fourth collaboration for its BrainTransporter technology further demonstrates the platform's long-term value beyond the Leqembi drug it helped develop for Alzheimer's disease, RBC Capital Markets analyst Natalia Webster writes. The new agreement with Eli Lilly is for the use of BrainTransporter with an undisclosed Lilly drug candidate for neurodegeneration. \"The continued cadence of deal-making validates the attractiveness of the platform and management's prior commentary around good opportunities for new strategic partnerships.\" BioArctic will receive $30 million upfront, and will be eligible to receive additional milestone payments of up to $770 million, as well as tiered mid-single-digit royalties on future global product sales. RBC rates BioArctic at outperform with a 280 Swedish kronor price target on the stock. Shares rise 4.2% to 312 kronor. (dominic.chopping@wsj.com) \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  June 22, 2026 03:56 ET (07:56 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"need_login_tip":false,"code":"91000000","status":"200"}}}